Want to see PRME full AI Analyst Report?
PRME Stock Chart & Stats
$3.58
$0.15(5.08%)
At close: 4:00 PM EDT
$3.58
$0.15(5.08%)
Day’s Range― - ―
52-Week Range$2.67 - $6.94
Previous CloseN/A
Volume304.95K
Average Volume (3M)2.68M
Market Cap
$651.14M
Enterprise Value$671.37
Total Cash (Recent Filing)$95.07M
Total Debt (Recent Filing)$112.48M
Price to Earnings (P/E)―
Beta2.83
Next Earnings
Oct 30, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding181,376,860
10 Day Avg. Volume2,900,960
30 Day Avg. Volume2,683,868
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.71Price Target Upside115.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$8.91M
Bulls Say, Bears Say
Bulls Say
Prime Editing PlatformA proprietary gene-editing platform can support multiple therapeutic programs and address genetic diseases at their DNA source. This creates durable pipeline optionality, although value depends on clinical validation, regulatory progress, and eventual commercialization.
PM647 Development Rights ClarifiedThe final arbitration outcome removes a material legal uncertainty around PM647 and confirms Prime’s ability to continue developing the candidate within the agreed field. Greater rights clarity can support resource allocation, partnering discussions, and long-term pipeline execution.
Governance StabilityContinued shareholder approval of the board and independent auditor supports organizational continuity during a capital-intensive development phase. Stable governance can help management maintain strategic focus, oversee clinical programs, and preserve reporting credibility as the pipeline advances.
Bears Say
Persistent Cash BurnSustained operating and free-cash-flow deficits indicate that PRME requires continuing external funding to advance its programs. Ongoing capital needs can dilute shareholders, increase financing risk, and constrain development priorities if market access or partnering support weakens.
Limited And Declining RevenueRevenue remains small, volatile, and insufficient to fund the company’s research platform, with the latest decline highlighting limited commercial traction. Until products or durable collaboration income scale materially, PRME remains highly dependent on financing and development milestones.
Leverage And Equity ErosionRising debt alongside rapid equity erosion has weakened PRME’s financial cushion and reduced flexibility to absorb further losses. A higher debt-to-equity profile may increase refinancing pressure and make future capital raising more costly or dilutive.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $2.67 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $651.14M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Oct 30, 2026 which is in 58 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.017.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.006 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 181,376,860 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went down -4.221%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.71 (115.48% Upside)
$7.71 (115.48% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$7.71
▲(115.48% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
13.25% Insiders
7.21% Mutual Funds
27.79% Other Institutional Investors
36.84% Public Companies and
Individual Investors